Valuation: Poxel

Market Cap 12.57M 14.39M 11.6M 10.69M 20.16M 1.39B 20.6M 139M 54.54M 679M 54.03M 52.84M 2.34B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 91.15M 73.5M 67.75M 128M 8.78B 131M 879M 346M 4.3B 342M 335M 14.8B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day-0.20%
1 week-2.16%
Current month-1.92%
1 month-0.20%
3 months-28.07%
6 months-17.18%
Current year-14.70%
1 week 0.2
Extreme 0.1964
0.21
1 month 0.19
Extreme 0.1942
0.21
Current year 0.19
Extreme 0.1942
0.48
1 year 0.19
Extreme 0.1942
0.61
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.84
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 10/06/2026
Director of Finance/CFO - 01/12/2022
Corporate Officer/Principal - 01/05/2023
Director TitleAgeSince
Chairman - 31/07/2025
Director/Board Member - 31/07/2025
Director/Board Member - 31/07/2025
Date Insider Type Main position Quantity % Market Cap.
2/4/22 A Fiscal year

Founder

67,000 0.2334%
2/4/22 A Fiscal year

Founder

6,666 0.0232%
1/30/21 A Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%-2.16%-66.23%-67.54% 12.27M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.52%-2.58%+29.87%+158.89% 23.36B
Weighted average by Cap. -2.80%-2.36%+39.54%+143.12%

Financials

2023 2024
Net sales 1.98M 2.27M 1.83M 1.68M 3.18M 218M 3.25M 21.85M 8.59M 107M 8.51M 8.33M 368M 6.64M 7.59M 6.12M 5.64M 10.64M 731M 10.87M 73.19M 28.79M 358M 28.52M 27.89M 1.23B
Net income -35.09M -40.15M -32.38M -29.85M -56.25M -3.87B -57.5M -387M -152M -1.89B -151M -147M -6.52B -18.3M -20.95M -16.89M -15.57M -29.35M -2.02B -30M -202M -79.41M -988M -78.66M -76.94M -3.4B
Net Debt 46.42M 53.12M 42.84M 39.49M 74.42M 5.12B 76.08M 512M 201M 2.51B 199M 195M 8.62B 67.08M 76.76M 61.9M 57.06M 108M 7.39B 110M 740M 291M 3.62B 288M 282M 12.46B
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
17/07/26 €0.1996 -0.20% 35,859
16/07/26 €0.2000 0.00% 14,856
15/07/26 €0.2000 -0.50% 18,951
14/07/26 €0.2010 +1.52% 35,305
13/07/26 €0.1980 -2.94% 78,822
  1. Stock Market
  2. Stocks
  3. POXEL Stock